Insider sales are economically immaterial (0.04% of market cap) and clustered just after a positive earnings report, likely liquidity-driven as blackout windows reopen. The COO's $128K sale is the largest, but still dwarfed by $283.7M cash and the $178.2M PRV gain. No bearish signal here; the earnings-fueled bull case (Danon Phase 2 data, extended runway) remains intact. Monitor for any 10b5-1 plan adoption by insiders or follow-on sales exceeding 0.5% of market cap before adjusting stance.
Drug in focus
RCKT drug pipeline →RP-A501
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 2 (pivotal/registrational)
- Time to market
- If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
- Next catalyst
- None dated
What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 21 $3.51entry
- T+1 · 3mo ago +0.57%α +0.86% · $3.53
- T+5 · 3mo ago +9.97%α +9.50% · $3.86
- T+20 · 8w ago −6.84%α −7.85% · $3.27
- T+60 · 20h ago −38.46%α −35.10% · $2.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a total of $164K in open-market sales over the past week. This cluster comes just 10 days after Q2 earnings that showed a GAAP net income of $123.2M, driven by a $178.2M PRV sale, extended cash runway into Q2 2028, and positive Danon disease Phase 2 data. However, sales are modest relative to the $401M market cap (0.04%), and the post-earnings timing aligns with a typical blackout-window opening, reducing informational significance per academic literature on cluster sells.
Key Financial Metrics
Key Facts
- CEO Gaurav Shah sold 2,293 shares at $3.381 for ~$8K on 2026-08-18.
- COO Christopher Stevens sold 36.7K shares at $3.50 for $128K on 2026-08-11.
- Total insider sales of $164K represent ~0.04% of the $401M market cap, below the 0.1% materiality threshold.
- Cluster occurred 10 days after a bullish Q2 earnings 8-K (GAAP net income $123.2M vs. $68.9M loss YoY, cash runway extended to Q2 2028).
- All four sales are open-market (code S), no 10b5-1 plan data provided, but post-earnings timing is consistent with routine blackout-window opening.
Financial Impact
Total insider sales of $164K, 0.04% of market cap. Trivial relative to $401M valuation and $283.7M cash position.
Risk Factors
- Insider sales cluster post-earnings may still unsettle retail holders given RCKT's 55% analyst bullish rating but $401M depressed market cap.
- If COO Stevens continues selling larger blocks in subsequent weeks, the pattern could shift from routine to concerning.
- No 10b5-1 plan disclosure, lack of formal trading plan increases uncertainty about intent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1787292248070 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers